Full Prescribing Information Important Safety Information
CLOSE
DOSING

STAY UP TO DATE

For the treatment of moderate to severe Vasomotor Symptoms (VMS)—commonly referred to as hot flashes and night sweats—due to menopause1,2

Woman spraying VEOZAHTM (fezolinetant) logo fire extinguisher at VMS fire

TREAT THE HEAT with 1 TABLET A DAY

Dosing and administration

VEOZAH sample box, sample bottle, and tablet

Tablet is not actual size.

Liver icon

Perform baseline bloodwork to evaluate for hepatic function and injury (ALT, AST, and serum bilirubin [total and direct]) before initiating VEOZAH. Do not start VEOZAH if ALT or AST is ≥2x the ULN or total bilirubin is elevated (e.g., ≥2x the ULN) for the evaluating laboratory. VEOZAH can be started if baseline hepatic transaminase evaluation is <2x the ULN and total bilirubin is normal.1

Perform follow-up evaluations of hepatic transaminase concentration at 3 months, 6 months, and 9 months after initiation of therapy and when symptoms (such as nausea, vomiting, or yellowing of the skin or eyes) suggest liver injury.1

ALT=alanine aminotransferase, AST=aspartate aminotransferase, ULN=upper limit of normal.

Dosing cup icon

Take VEOZAH 45 mg with liquids and swallow whole. Do not cut, crush, or chew tablets.1

Stopwatch icon

If a dose is missed or not taken at the usual time, patients should take the missed dose as soon as possible, unless there are fewer than 12 hours before the next scheduled dose. Return to the regular schedule the following day.1

VEOZAH sample box, sample bottle, and tablet

Tablet is not actual size.

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

  1. Known cirrhosis
  2. Severe renal impairment or end-stage renal disease
  3. Concomitant use with CYP1A2 inhibitors

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

INDICATIONS AND USAGE

VEOZAH™ (fezolinetant) is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

CONTRAINDICATIONS

VEOZAH is contraindicated in women with any of the following:

  1. Known cirrhosis
  2. Severe renal impairment or end-stage renal disease
  3. Concomitant use with CYP1A2 inhibitors

WARNINGS AND PRECAUTIONS

Hepatic Transaminase Elevation

Elevations in serum transaminase [alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)] levels > 3x the upper limit of normal (ULN) occurred in 2.3% of women receiving VEOZAH and 0.9% of women receiving placebo in three clinical trials. No serum elevations in total bilirubin (> 2x ULN) occurred. Women with ALT or AST elevations were generally asymptomatic. Transaminase levels returned to pretreatment levels (or close to these) without sequelae with dose continuation, and upon dose interruption, or discontinuation. Women with cirrhosis were not studied.

Perform baseline bloodwork to evaluate for hepatic function and injury prior to VEOZAH initiation. Do not start VEOZAH if concentration of ALT or AST is ≥ 2x ULN or if the total bilirubin is elevated (e.g., ≥ 2x ULN) for the evaluating laboratory. If baseline hepatic transaminase evaluation is < 2x ULN and the total bilirubin is normal, VEOZAH can be started. Perform follow-up evaluations of hepatic transaminase concentration at 3 months, 6 months, and 9 months after initiation of therapy and when symptoms (such as nausea, vomiting, or yellowing of the skin or eyes) suggest liver injury.

ADVERSE REACTIONS

The most common adverse reactions with VEOZAH ≥ 2% and > placebo (VEOZAH % vs. placebo %) are: abdominal pain (4.3% vs. 2.1%), diarrhea (3.9% vs. 2.6%), insomnia (3.9% vs. 1.8%), back pain (3.0% vs. 2.1%), hot flush (2.5% vs. 1.6%), and hepatic transaminase elevation (2.3% vs. 0.8%).

Please click here for full Prescribing Information for VEOZAH™ (fezolinetant).

REFERENCES: 1. VEOZAH [package insert]. Northbrook, IL: Astellas Pharma US, Inc. 2. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55.

THIS WEBSITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS ONLY.

I certify that I am a healthcare professional in the US.

NO